Discover · The Research Behind It
Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline — Farrell et al., Can Fam Physician 2017
Last checked
- Free
- Worldwide
- Research paper
- Reading
- Online
Never stop or reduce a prescribed medicine on your own: some medicines cause withdrawal effects or a relapse if they are stopped or cut down too quickly. Use these resources to plan it with your prescriber.
- Published in
- Canadian Family Physician, 2017
- Evidence
- Moderate
- Cost
- Free.
What is this paper about?
Guideline from the deprescribing.org team, built with GRADE methods, a systematic review of trials of reducing or stopping proton pump inhibitors and reviews of harms of long-term use. It recommends that adults who have taken a PPI for at least four weeks for heartburn, mild-to-moderate reflux or oesophagitis, and whose symptoms have settled, be offered a lower dose, use only when needed, or stopping.
Why is it in the directory?
Backs up deprescribing.org and the Canadian Deprescribing Network in chapter 06, and gives useful background to readers of chapter 15's gastroenterology listings who take long-term reflux medicine.
Is it free to read?
Evidence-based clinical practice guideline (GRADE) with a systematic review of PPI deprescribing trials. Moderate evidence. Can Fam Physician 2017;63(5):354–364. Free full text in PubMed Central (PMC5429051).
About the paper
- Authors
- Farrell B, Pottie K, Thompson W, et al.
- Published in
- Can Fam Physician 2017;63(5):354–364
- Kind of study
- Evidence-based clinical practice guideline (GRADE) with a systematic review of PPI deprescribing trials
- Strength of evidence
- Moderate — good studies, but fewer of them or with some limits
- Free to read
- Free in PMC (© College of Family Physicians of Canada)
Good to know
- Does not apply to people with Barrett's oesophagus, severe oesophagitis or a history of bleeding ulcers; the evidence dates from 2017.
Where it sits in the directory
Listed under “Coming Off Medication Safely — Tapering & Deprescribing” in chapter 17 of the directory, The Research Behind It, with 12 other listings in the same category.
Similar listings
Also in the directory, with why each one is here.
- Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline — Pottie et al., Can Fam Physician 2018
Also a free research paper available worldwide, also for clinicians, in the same category.
This deprescribing.org guideline recommends offering a slow taper to adults aged 65 or over who take benzodiazepines or Z-drugs for insomnia, whatever the duration of…
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 — Dowell et al., MMWR Recomm Rep 2022
Also a free research paper available worldwide, also for clinicians, in the same category.
The US national guideline on opioids for pain (not for sickle cell disease, cancer or end-of-life care).
- Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults — NICE 2022
Also a free research paper available worldwide, also for clinicians, in the same category.
NICE's guideline on withdrawing opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants.
- A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? — Davies & Read, Addict Behav 2019
Also a free research paper available worldwide, also for clinicians, in the same category.
Reviewed 24 studies to test UK and US guideline statements that antidepressant withdrawal is 'self-limiting', typically resolving within one to two weeks.
- Deprescribing.org
A free tool or directory for people in Canada, also for clinicians, listed under “Medication Tapering & Deprescribing Directories” in Support Groups & Communities.
Evidence-based resources and tools for safely reducing or stopping medications, including deprescribing algorithms.
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis — Nong et al., BMJ 2026
Also a free research paper available worldwide, also for clinicians, listed under “Metabolic Therapies” in the same chapter.
At one year, compared with lifestyle change alone, tirzepatide gave the most extra weight loss (14.9%), then cagrilintide-semaglutide (14.8%), oral semaglutide (10.9%)…
This page sums up the listing in Notbroken’s own words, from the provider’s own pages; Notbroken does not run it. A listing is not a recommendation, and Notbroken hasn’t tested the service. The details were last checked against the paper and its listing on 25 October 2026. Page first published 7 November 2026. Services, prices and opening hours change, so check with the provider before you rely on them. General information, not medical, legal or financial advice. How these pages work · Run this service? Ask for a change.